Clinical Trial

Study of AHB-171 in Chronic Hepatitis B Participants

Study acronym: EXTEND-101
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB). Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.
Trial Details
NCT Number NCT07617194
Lead Sponsor AusperBio Therapeutics Inc.
Conditions Hepatitis B, Chronic
Enrollment 144 participants
Start Date 2026-07-06
Primary Completion 2027-10-08 (estimated)
Study Completion 2028-08-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-01